ABSI three-lens brief
Evidence-based stock research on ABSI. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA above 200-day MA (golden-cross regime); price above both. · Currently unprofitable on a trailing basis — no P/E multiple available.
- 50-day MA above 200-day MA (golden-cross regime); price above both.
- Currently unprofitable on a trailing basis — no P/E multiple available.
- Analyst mean target $14.82 — 46% above current (11 analysts).
- Negative free cash flow last quarterly (-$50.59M).
- Reported earnings on 2026-11-12.
ABSI closed at $10.12 (+1.50%) as of 2026-11-12. Market cap: $1.74B. Price is above the 50-day MA and above the 200-day MA. Positives: 50-day MA above 200-day MA (golden-cross regime); price above both.; analyst mean target $14.82 — 46% above current (11 analysts).. Concerns: currently unprofitable on a trailing basis — no P/E multiple available.; negative free cash flow last quarterly (-$50.59M).. Last quarter: Revenue $318.0K, net income -$33.21M, free cash flow -$50.59M. Watching for: 2026-11-12 earnings release (today).
Why three lenses on ABSI, not one.
A single reasoning model has blind spots it doesn’t know about. We examine ABSI across Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://www.clearpathinvest.app/embed/ABSI" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath ABSI brief"></iframe>